OSTX
OS Therapies Inc
$1.46
-0.13 (-8.18%)
At close · Jul 8
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed May 18, 2026
Market Cap
$65.03M
Shares
44,538,106
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.46
Open$1.53
Day$1.43–1.53
52W$1.15–2.57
Avg vol 30d862K
Short int2.0M · 4.6% float · 3.2d
Short vol39%
DataAug 2024–Jul 2026
Filing10-Q · May 18
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
−18%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
−5%
trailing
YTD return
+4%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
2 of 29 funds reported for Jun 30 · net -29.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.56% of float · ▲ +22.6% MoM · 3.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
29 holders — near 1-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
11.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 18, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
2 of 29 funds reported for Jun 30 · net -29.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.56% of float · ▲ +22.6% MoM · 3.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
29 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 22%
52-wk high $3
vs 200-day avg -12%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OSTX
this stock
OS Therapies Inc
|
$65.03M | +4.3% | — | — | 4.6% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OSTX | -23.2% | -18.4% | -5.2% | -23.2% | +4.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -23.0% | -19.3% | -12.6% | -23.0% | -5.0% |